Скачать или смотреть Accelerating Drug Discovery for MASLD Using High Content Imaging in HEPATOPAC

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a prevalent and serious health condition, driving the urgent need for new therapeutic strategies. Advanced in vitro models, such as HEPATOPAC®, are being used to study the mechanisms of MAFLD and support drug discovery. By exposing these cultures to free fatty acids and high glucose/fructose, researchers can replicate key features of liver steatosis and analyze changes in lipid accumulation and gene expression.

Dr. Cottier will discuss a number of studies utilizing HEPATOPAC® cultures to model aspects of fatty liver disease to enable the evaluation of potential therapeutic targets, including small molecules and siRNA-based approaches, to modulate disease progression. These studies will highlight the use of high content imaging (HCI) as a method for automating and increasing throughput for these analyses.

Download the slides: https://info.bioivt.com/bioivt-webina...
Additional resources on this topic: https://bioivt.com/resources/educatio...
Questions, comments and requests: https://bioivt.com/about/contact-us
Access BioIVT's products and services: https://bioivt.com
Other previously aired webinars: https://bioivt.com/educational-conten...)
Upcoming webinar notifications: https://bioivt.com/resources/newslett...

About the presenter
Karissa Cottier, Senior Scientist and Manager of R&D at BioIVT, earned her PhD in medical pharmacology at University of Arizona where she focused on drug delivery in migraine headache model. In her post-doctoral fellowship at Johns Hopkins University Karissa utilized molecular and histology-based assays in an in vitro model to study cerebral malaria. We at BioIVT were pleased that Karissa decided to join our team in our lab in Baltimore Maryland following her post-doc. She has contributed to numerous projects, and importantly led our program to develop high-purity Kupffer cells as well as investigate new applications for our HEPATOPAC and HEPATOMUNE cultures.